World journal of clinical oncology最新文献

{"title":"Efficacy and safety of warming Yang and dredging intestines method in metastatic colon cancer maintenance.","authors":"Yu-Xing Sun, Tong Zhang, Jiang-Yu Bian, Wen-Ting He, Xue-Qian Wang, Chuan-Bo Liu","doi":"10.5306/wjco.v16.i6.105175","DOIUrl":"10.5306/wjco.v16.i6.105175","url":null,"abstract":"<p><strong>Background: </strong>There is a lack of integrated Chinese and Western medicine treatment regimens supported by high-level evidence-based medicine in the maintenance therapy phase of metastatic colorectal cancer (mCRC). Based on the traditional Chinese medicine theory of \"Yin tumor\", we believe that \"Yang does not transform Yin, and it is blocked in the intestines\" is the core pathogenesis of mCRC. Based on the basic treatment principle of \"warming Yang and dredging intestines\", we developed the Quxie Capsule. Previous randomized controlled clinical trials demonstrated that the Quxie Capsule can significantly prolong the overall survival of patients with mCRC, but it remains to be verified whether the combination of the \"warming Yang and dredging intestines method\" prescription with Western medicine standard regimen can prolong the efficacy and safety of the mCRC during the period of maintenance therapy.</p><p><strong>Aim: </strong>To confirm and clinically validate that the combination of \"warming Yang and dredging intestines method\" prescription with Western medicine standard regimen can prolong progression-free survival (PFS) during maintenance treatment of mCRC. The safety of \"warming Yang and dredging intestines method\" prescription is also assessed.</p><p><strong>Methods: </strong>The study has a prospective, open-label, randomized, controlled study design. Patients have been recruited beginning November 2023 from Xiyuan Hospital of China Academy of Chinese Medical Sciences, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Dongfang Hospital of Beijing University of Chinese Medicine, and Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine. The study period is from March 2024 to March 2026. After screening in outpatient clinics or wards, subjects who met the inclusion criteria are randomized into the treatment or control group in a 2:1 ratio. The treatment group receives the \"warming Yang and dredging intestines method\" formula combined with Western standard maintenance therapy. The control group receives Western standard maintenance therapy formulated by the investigators based on the Chinese Society of Clinical Oncology guidelines for colorectal cancer. All participants receive treatment until the occurrence of disease progression, death, or unmanageable adverse effects, with post-treatment monitoring continued until mortality. An independent panel of chief physicians with extensive clinical experience evaluates the progression of the disease.</p><p><strong>Results: </strong>This study aims to clarify whether the combination of warming Yang and dredging intestines method formula with standard Western medicine regimens can prolong PFS during maintenance therapy for mCRC and whether the treatment has a favorable safety profile. The goal is to provide a combined Chinese and Western medicine treatment option for clinical physicians and mCRC patients. Notably, with the actual sample size, this s","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105175"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for the comprehensive treatment of gastric cancer ovarian metastasis.","authors":"Si-Jia Wu, Chu-Ying Wu, Kai Ye","doi":"10.5306/wjco.v16.i6.106589","DOIUrl":"10.5306/wjco.v16.i6.106589","url":null,"abstract":"<p><p>The incidence of gastric cancer is currently increasing, with gastrectomy and D2 Lymphadenectomy being the primary treatments for resectable gastric cancer. For advanced or unresectable metastatic gastric cancer, systemic treatment options include chemotherapy, targeted therapy, or immunotherapy. Krukenberg tumours are types of metastatic tumours in the ovaries that exclusively occur in female patients and that originate from the stomach. Previously deemed an incurable stage of advanced disease, the prognosis of patients with ovarian metastases from gastric cancer depends on multiple factors, including tumour biology and treatment response. With the development of comprehensive cancer treatment options, the combination of surgery and chemotherapy has gradually become the primary treatment for patients with ovarian metastasis from gastric cancer. Individualised comprehensive treatment regimens are crucial for improving patient outcomes. This review summarises the comprehensive treatment strategies for ovarian metastasis from gastric cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"106589"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and challenges in pathomics for liver cancer: From diagnosis to prognostic stratification.","authors":"Ming-Hui Peng, Kai-Lun Zhang, Shi-Wei Guan, Quan Lin, Hai-Bo Yu","doi":"10.5306/wjco.v16.i6.107646","DOIUrl":"10.5306/wjco.v16.i6.107646","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC), a leading cause of cancer mortality, faces diagnostic and therapeutic challenges due to its histopathological complexity and clinical heterogeneity. Pathomics, an emerging discipline that integrates artificial intelligence (AI) with quantitative pathology image analysis, aims to decode disease heterogeneity by extracting high-dimensional features from histopathological specimens. This review highlights how AI-driven pathomics has revolutionized liver cancer management through automated analysis of whole-slide images. Pathomics integrates deep learning with histopathological features to enable precise tumour classification (<i>e.g.</i>, HCC <i>vs</i> cholangiocarcinoma), microvascular invasion (MVI) detection, recurrence risk stratification, and survival prediction. Advanced frameworks such as MVI-AI diagnostic model and CHOWDER demonstrate high accuracy in identifying prognostic biomarkers, whereas multiomics integration links morphometric patterns to molecular signatures (<i>e.g.</i>, <i>EZH2</i> expression and immune infiltration). Despite these breakthroughs, critical bottlenecks persist, including limited multicentre validation studies, \"black box\" model interpretability, and clinical workflow integration. Future studies should emphasize AI-enhanced multimodal fusion (radiogenomics and liquid biopsy) and standardized platforms to bridge computational pathology and precision oncology, ultimately improving personalized therapeutic strategies for liver malignancies. This synthesis aims to guide research translation and advance personalized therapeutic strategies for liver malignancies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"107646"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiota and cancer: Elucidating the role of <i>Candida albicans</i> in cancer progression.","authors":"Di Wang, Hao-Ling Zhang, Hao-Long Zhang, Zhi-Jing Song, Sandai Doblin, Ping Lu","doi":"10.5306/wjco.v16.i6.106847","DOIUrl":"10.5306/wjco.v16.i6.106847","url":null,"abstract":"<p><p><i>Candida albicans</i> (<i>C. albicans</i>) represents one of the most prevalent opportunistic fungal pathogens in cancer patients. Although the association between <i>C. albicans</i> and cancer has been recognized for decades, the causal relationship, whether <i>C. albicans</i> infection is a consequence of cancer or a direct contributor to cancer development-remains a subject of intensive investigation. Recently, the complex interplay between microbes and cancer has garnered significant attention within the scientific community, with growing interest in elucidating the underlying molecular mechanisms. This review systematically examines the biological characteristics of <i>C. albicans</i>, its multifaceted interactions with the host, and its relationship with the intestinal microbiota. Additionally, it provides a comprehensive analysis of the association between <i>C. albicans</i> and the development of various malignancies, with particular emphasis on digestive tract cancers. The review also identifies critical knowledge gaps and apparent contradictions in existing research, highlighting potential avenues for breakthroughs that will advance the efficient and accurate screening, diagnosis, and treatment of cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"106847"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable complete response to sintilimab plus chemotherapy in gallbladder cancer with extensive metastasis: A case report.","authors":"Feng Wang, Xin-Lei Gong, Xin-Ni Chen, Zhi-Hui Yang, Xiao-Yuan Chu","doi":"10.5306/wjco.v16.i6.105910","DOIUrl":"10.5306/wjco.v16.i6.105910","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder cancer is a highly malignant and aggressive tumor, often diagnosed at an advanced stage. The prognosis for advanced gallbladder cancer remains poor, with limited options for effective treatment.</p><p><strong>Case summary: </strong>A 65-year-old male patient presented with a soft tissue mass in the gallbladder. Following laparoscopic exploration, he underwent radical surgery for gallbladder cancer, with the tumor staged as pT2N1M0 (stage III). Post-surgery, the patient received four cycles of adjuvant chemotherapy. However, one month later, over 60 metastatic lesions were detected in the liver, lungs, and lymph nodes. In response to the widespread metastasis, he underwent six cycles of combination therapy consisting of sintilimab, albumin-bound paclitaxel, and cisplatin. After two cycles, a partial response was achieved. Maintenance therapy was initiated with a combination of sintilimab and albumin-bound paclitaxel for four cycles. Monotherapy with sintilimab was continued thereafter until October 2023. Complete remission was confirmed in September 2021. The patient sustained this complete response for more than three years, including an eleven-month period without disease progression following the discontinuation of sintilimab. Genetic analysis revealed a tumor mutational burden of 15.4 mutations/megabase, which indicates a potentially favorable response to immunotherapy.</p><p><strong>Conclusion: </strong>This case demonstrates the potential of combining immunotherapy (sintilimab) with chemotherapy to achieve durable remission in metastatic gallbladder cancer, even in a patient with extensive metastasis. In addition, it indicated the importance of tumor mutational burden as a predictive biomarker of immunotherapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105910"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic factors in patients with malignant melanoma: A Chinese prospective cohort study.","authors":"Long Tang, Yi-Yao Wang, Hai-Ke Lei, Chun-Mei Wang, Yan Teng, Qian-Jie Xu, Qing-Ming Jiang, Biao Chen, Xiang-Hua Zeng, Bian-Qin Guo, En-Wen Wang","doi":"10.5306/wjco.v16.i6.105813","DOIUrl":"10.5306/wjco.v16.i6.105813","url":null,"abstract":"<p><strong>Background: </strong>Melanoma is a highly malignant tumor that has an extremely poor prognosis. It is the primary cause of death among cutaneous malignancies, accounting for 75% of such fatalities; approximately 325000 new cases and 57000 deaths were reported worldwide in 2020. The main modalities for melanoma treatment include surgery, immunotherapy, targeted therapy, high-dose interferon, antitumor angiogenesis, chemotherapy, and radiotherapy. Due to China's special national conditions, the main pathological types and therapeutic effects are greatly different from those in Europe and the United States, so more studies are needed to determine the curative effects of such treatments in the Chinese population.</p><p><strong>Aim: </strong>To explore their clinical characteristics, prognostic influencing factors and real-world data to provide a reference basis for further diagnosis and treatment.</p><p><strong>Methods: </strong>We collected pathological data from patients diagnosed with malignant melanoma in our hospital in recent years. Univariate analysis was conducted using the log-rank test, while multivariate analysis was performed with the Cox proportional hazard regression model. The survival rate was calculated using the Kaplan-Meier method.</p><p><strong>Results: </strong>The male-to-female patient ratio was 1.04: 1. Among the clinical classifications, melanoma of the limb accounted for 47.56% of cases, followed by melanoma of the skin (18.18%) and mucosal melanoma (18.05%). The 5-year survival rates for stage I-II, stage III, and stage IV patients were 54.65%, 37.88%, and 28.58%, respectively. Univariate analysis revealed that age, tumor stage, treatment mode, platelet count at the first visit, and lactate dehydrogenase (LDH) level were significantly related to patient survival. Patients with high LDH and high platelet counts exhibited significantly lower survival rates at 1 year, 3 years, and 5 years. Multivariate analysis demonstrated that tumor stage, chemotherapy, interferon therapy, and LDH level were independent risk factors affecting patient survival and prognosis. Compared to the mortality rates of patients who did not receive chemotherapy or interferon therapy, those of patients who received chemotherapy and interferon therapy were 30.0% and 44.5% lower, respectively. Additionally, patients with elevated LDH levels were 2.27 times more likely to die than patients with normal LDH levels.</p><p><strong>Conclusion: </strong>Melanoma is highly malignant, and its prognosis is influenced by numerous factors, resulting in an overall poor prognosis. This study identified several factors that impact patient prognosis, providing a foundation for individualized comprehensive treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105813"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of nutritional and inflammatory markers in colorectal cancer.","authors":"Jon Andreescu, Abrahams Ocanto, Felipe Couñago","doi":"10.5306/wjco.v16.i6.104958","DOIUrl":"10.5306/wjco.v16.i6.104958","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related mortality worldwide, responsible for approximately 900000 deaths annually. Inflammation and malnutrition significantly influence patients' responses to treatment. Markers such as serum albumin concentration, the prognostic nutritional index, nutritional risk index (NRI), geriatric NRI, and the systemic immune-inflammation index enable the early identification of high-risk patients, facilitating timely interventions that can improve survival and reduce morbidity. A comprehensive understanding and application of these markers allow for better risk stratification in CRC patients, optimizing their management and outcomes.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"104958"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus.","authors":"Shuai Liu, Yao-Hui Liu, Hong-Bo Ni, Jia-Jian Li, Ze-Tao Wu, Luo-Luo Wang, Yi Ruan, Xin-Hua Zhou","doi":"10.5306/wjco.v16.i6.106798","DOIUrl":"10.5306/wjco.v16.i6.106798","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma with portal vein tumor thrombus (HCC-PVTT) is a severe condition with poor prognosis. While transarterial chemoembolization (TACE) combined with lenvatinib (TACE-L) shows some promise, survival outcomes remain suboptimal. We hypothesize that TACE-L plus programmed cell death protein-1 inhibitors (TACE-L-P) may offer superior survival benefits compared to TACE-L in this patient population.</p><p><strong>Aim: </strong>To compare efficacy and safety of TACE-L-P <i>vs</i> TACE-L in HCC-PVTT and identify prognostic factors.</p><p><strong>Methods: </strong>Data from HCC-PVTT patients treated with TACE-L-P or TTACE-L from January 2018 to December 2023 were collected and retrospectively analyzed. Propensity score matching (PSM) method with optimal matching was used to minimize confounding bias. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (AEs) were compared between the two groups. Independent prognostic factors for OS and PFS were elucidated using the Cox proportional hazards model.</p><p><strong>Results: </strong>A total of 100 patients were included, with 42 patients in the TACE-L-P group and 68 patients in the TACE-L group. After PSM performing optimal matching, baseline characteristics were well balanced between the two groups, each comprising 42 patients. The median OS was significantly longer in the TACE-L-P group compared to the TACE-L group (17.2 months <i>vs</i> 12.6 months, <i>P</i> = 0.0207), as was the median PFS (10.6 months <i>vs</i> 7.1 months, <i>P</i> = 0.012). The ORR and disease control rate were both superior in the TACE-L-P group compared to the TACE-L group (66.7% <i>vs</i> 42.9%, <i>P</i> = 0.049; 78.6% <i>vs</i> 50.0%, <i>P</i> = 0.012). Multivariate analysis revealed that the independent prognostic factors for both OS and PFS were the treatment regimen and extrahepatic metastasis. The incidence of any-grade and grade 3 AEs was comparable between the TACE-L-P and TACE-L groups (84.5% <i>vs</i> 88.1%, <i>P</i> = 0.546), with no occurrences of grade 4/5 AEs or treatment-related mortality in either group.</p><p><strong>Conclusion: </strong>Compared to TACE-L, the TACE-L-P regimen exhibits an acceptable safety profile and shows potential in improving survival outcomes, making it a promising therapeutic option for patients with HCC-PVTT.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"106798"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depression in gastric cancer patients: Integrated therapeutic strategies and clinical implications.","authors":"Pei-Yuan Yu, Feng Liu, Yan Jiao, Yue-Chen Zhao, Ya-Hui Liu","doi":"10.5306/wjco.v16.i6.106229","DOIUrl":"10.5306/wjco.v16.i6.106229","url":null,"abstract":"<p><p>Depression is a common comorbidity in gastric cancer (GC) patients, with prevalence rates reaching up to 57%, particularly in advanced stages and during active treatment. While prior studies have explored the bidirectional relationship between GC and depression, this editorial provides a structured synthesis of therapeutic strategies including pharmacological, psychotherapeutic, integrative, and biomarker-driven interventions, within a multidisciplinary care framework. Depression may exacerbate tumor progression through chronic stress and neurotransmitter dysregulation, such as β2-adrenergic receptor activation, while the cancer burden deepens psychological distress. Antidepressants, especially selective serotonin reuptake inhibitors, have demonstrated efficacy in alleviating depressive symptoms in up to 70% of cases, particularly when used alongside chemotherapy. Psychotherapeutic modalities, including cognitive-behavioral therapy and family-based interventions, help reduce depressive symptoms, improve coping mechanisms, and prevent relapse. Integrative strategies like music therapy, mindfulness, and physical activity further support emotional well-being, particularly in mild-to-moderate depression. Multidisciplinary care that combines nutritional support, pain control, and psychosocial interventions is essential. Notably, the integration of interventional therapies with traditional Chinese medicine has shown potential in stabilizing tumor growth and improving mental health, enabling functional \"tumor-bearing survival\". Emerging immunotherapies such as cadonilimab may also contribute indirectly to depression alleviation by enhancing treatment efficacy and extending survival. Future research should focus on biomarker-guided approaches, such as targeting β2-adrenergic signaling, and developing personalized psychosocial care models. A holistic approach that integrates both physical and psychological care is vital to improving outcomes and quality of life in GC patients.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"106229"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High hypoxia inducible factor-1α expression is associated with reduced survival in patients with breast cancer: A meta-analysis.","authors":"Xue-Di Zheng, Huan-Yu Li, Si-Yu Gao, Qi Wang, Jiang-Bo Liu","doi":"10.5306/wjco.v16.i6.105691","DOIUrl":"10.5306/wjco.v16.i6.105691","url":null,"abstract":"<p><strong>Background: </strong>Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the prognosis of breast cancer, but the current evidence remains inconclusive.</p><p><strong>Aim: </strong>To provide comprehensive evidence about the correlation of altered HIF-1α expression with overall survival (OS) and disease-free survival (DFS) in breast cancer patients.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Embase, and Web of Science databases to collect relevant articles that were published before April 8, 2024. A meta-analysis was used to assess the impact of altered HIF-1α expression on the OS and DFS of breast cancer patients. Subgroup and sensitivity analyses were also performed in this meta-analysis.</p><p><strong>Results: </strong>This meta-analysis included 40 studies. The average percentage of breast cancer patients with high HIF-1α expression was 39.6%. The overall meta-analysis results demonstrated that high HIF-1α expression is strongly linked to poor outcomes in patients of breast cancer. Compared with low HIF-1α expression, the overall hazard ratio for OS in patients with high HIF-1α expression was 1.47 [95% confidence interval (CI): 1.29-1.69], and the overall hazard ratio for DFS was 1.82 (95%CI: 1.56-2.12). Furthermore, both OS [1.18 (95%CI: 1.01-1.38)] and DFS [1.79 (95%CI: 1.03-3.11)] were markedly shorter in triple-negative breast cancer cases with high HIF-1α expression. Subgroup analysis revealed that the antibody used to detect HIF-1α expression affected only the correlation linking HIF-1α expression to DFS in breast cancer patients (<i>P</i> = 0.0004). Furthermore, the sensitivity analysis demonstrates that the overall conclusions of the meta-analysis were unaffected by the removal of individual studies.</p><p><strong>Conclusion: </strong>Compared to patients with low HIF-1α expression, those with high expression level had shorter OS and DFS. However, the prognostic significance of high HIF-1α expression varies across molecularly stratified breast cancer cohorts needs to be further elucidated.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105691"},"PeriodicalIF":2.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}